A malignant melanoma is a highly lethal melanocytic neoplasm. A neoplasm usually affects the skin. Malignant melanomas in the head and neck region are rare, accounting for less than 1% of all melanomas. Malignant melanoma of the nose and paranasal sinuses is an aggressive disease typically presenting at an advanced stage, with a 5-year survival rate ranging 20-30%. Melanomas are tumors arising from melanocytes, which are neuroectodermally derived cells located in the basal layers of the skin. This is a case report of a 35-year-old male, who presented with very aggressive disease and developed liver metastasis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4668721 | PMC |
| http://dx.doi.org/10.4103/0975-5950.168216 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Discrepancy Between Patient-Reported and Physician-Prescribed Chemoprevention in Patients With Keratinocyte Carcinomas.
Int J Dermatol
March 2025
Department of Dermatology, University of Nebraska, Omaha, Nebraska, USA.
Primary Cutaneous Neoplasm With Rhabdomyosarcomatous Differentiation and a Melanoma-Like Mutational Landscape.
J Cutan Pathol
March 2025
Department of Pathology and Laboratory Medicine, Cleveland Clinic, Cleveland, Ohio, USA.
Malignant melanoma (MM) is notorious for its wide range of morphologic variability. Rarely, MM may lose all melanocytic markers and adopt the morphologic and immunophenotypic characteristics of a different neoplasm in a process known as trans-differentiation (TMM). Distinguishing TMM from primary cutaneous neoplasms may be challenging and is often dependent on the identification of an adjacent conventional melanoma.
View Article and Find Full Text PDFTransdermal sequential delivery of functionalized Nano-Deep eutectic system for enhanced treatment of melanoma.
Int J Pharm
March 2025
Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming 650500, PR China. Electronic address:
In the present study, we introduce the concept of "transdermal sequential delivery" as a non-invasive and synergistic approach for the treatment of melanoma. We developed a functionalized Deep Eutectic System (DES) that incorporates both small molecule drugs and nanoparticles. The glycolysis inhibitor 2-deoxy-D-glucose (2-DG) served as the Hydrogen Bond Donor (HBD) to form the DES, while glutathione (GSH)-responsive Mesoporous Organosilicon Nanoparticles (MON) were prepared and encapsulated with chlorin e6 (Ce6).
View Article and Find Full Text PDFImmune checkpoint inhibition in metastatic or non-resectable melanoma after failure of adjuvant anti-PD-1 treatment. A EUMelaReg real-world evidence study.
Eur J Cancer
March 2025
National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark.
Background: Adjuvant immune checkpoint inhibition (ICI) with anti-PD-1 antibodies in high-risk resected melanoma has been shown to improve recurrence-free survival. It is unclear whether prior adjuvant anti-PD-1 therapy is associated with altered response to subsequent ICI treatment in the metastatic setting.
Methods: Using data from the European Melanoma Registry (EUMelaReg), we analyzed the efficiency of first-line (1L) ICI in non-resectable or metastatic melanoma after failure from prior adjuvant anti-PD-1 treatment.
The COVID-19 Pandemic and Delays in Melanoma Treatment: A National Cancer Database Study.
J Surg Res
March 2025
Department of Surgery, Boston Medical Center, Boston University Chobanian and Avedisian School of Medicine, Boston, Massachusetts. Electronic address:
Introduction: Timely treatment for patients with melanoma is critical. This study evaluated associations between the COVID-19 pandemic and time to treatment for patients with melanoma and delineated factors associated with delayed treatment.
Methods: Using the National Cancer Database, patients with cutaneous melanoma were categorized using year of diagnosis: COVID era (2020) versus pre-COVID era (2018-2019).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!